Drug Profile
Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology/Shanghai Biomabs Pharmaceutical
Alternative Names: Aomaishu; CMAB-007Latest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology
- Developer Shanghai Biomabs Pharmaceuticals
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Allergic asthma
Most Recent Events
- 13 Sep 2022 Taizhou Mabtech Pharmaceutical completes a phase I trial for Asthma (In volunteers) in China (SC, Injection) (NCT05897008)
- 07 Feb 2022 Taizhou Mabtech Pharmaceutical initiates a phase I trial for Asthma (In volunteers) in China (SC, Injection) (NCT05897008)
- 25 May 2021 Taizhou Mabtech Pharmaceutical completes a phase I trial in Asthma (In volunteers) in the China (SC) (NCT04778137)